Trial · NCT03083769
Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation.
NCT03083769, Completed, Southern Medical University, China; results first posted 2019-11-20
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation. Trials, record NCT03083769. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03083769
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Functional Genetic Variants Affecting Tacrolimus Trough Levels and Side Effects in Chinese Renal Transplantation.
- NCT number
- NCT03083769
- Status
- Completed
- Enrollment
- 1,502 participants, actual
- Lead sponsor
- Southern Medical University, China
- Conditions
- Transplantation
- First posted
- 2017-03-20
- Last updated
- 2019-11-20
- Results first posted
- 2019-11-20
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants With Acute Rejection | Day 1 to Day 61 | We will measure the number of participants with acute rejection during the day 1 to day 61 after transplantation. Kaplan-Meier analyses were performed for acute rejection in participants with different genotypes. |
| Primary | Number of Participants With Tacrolimus-related Nephrotoxicities | Day1 to Day 61 | We will measure the number of participants with tacrolimus-related nephrotoxicities during the day 1 to day 61 after transplantation. Kaplan-Meier analyses were performed for tacrolimus-related nephrotoxicities in participants with different genotypes. |
| Primary | Number of Participants With Tacrolimus-related Neurotoxicities | Day1 to Day 61 | We will measure the number of participants with tacrolimus-related neurotoxicities during the day 1 to day 61 after transplantation. Kaplan-Meier analyses were performed for tacrolimus-related neurotoxicities in participants with different genotypes. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants With Acute Rejection | Day 1 to Day 61 | participants | NUMBER | |
| PRIMARY | Number of Participants With Tacrolimus-related Nephrotoxicities | Day1 to Day 61 | participants | NUMBER | |
| PRIMARY | Number of Participants With Tacrolimus-related Neurotoxicities | Day1 to Day 61 | participants | NUMBER |
Source ClinicalTrials.gov
Results by group6
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants With Acute Rejection | Cohort 1 | 256 | participants | ||
| Number of Participants With Acute Rejection | Cohort 2 | 37 | participants | ||
| Number of Participants With Tacrolimus-related Nephrotoxicities | Cohort 1 | 26 | participants | ||
| Number of Participants With Tacrolimus-related Nephrotoxicities | Cohort 2 | 2 | participants | ||
| Number of Participants With Tacrolimus-related Neurotoxicities | Cohort 1 | 10 | participants | ||
| Number of Participants With Tacrolimus-related Neurotoxicities | Cohort 2 | 1 | participants |
Source ClinicalTrials.gov
Participant flow6
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Cohort 1 | 839 | |
| Overall Study | STARTED | Cohort 2 | 663 | |
| Overall Study | COMPLETED | Cohort 1 | 819 | |
| Overall Study | COMPLETED | Cohort 2 | 631 | |
| Overall Study | NOT COMPLETED | Cohort 1 | 20 | |
| Overall Study | NOT COMPLETED | Cohort 2 | 32 |
Source ClinicalTrials.gov
Adverse events2
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | Acute rejection | Renal and urinary disorders | Cohort 1 | 256 | 819 | 256 |
| serious | Acute rejection | Renal and urinary disorders | Cohort 2 | 37 | 631 | 37 |
Source ClinicalTrials.gov
Adverse event totals6
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Cohort 1 | 0 | 819 |
| Total, all-cause mortality | Cohort 2 | 0 | 631 |
| Total, other adverse events | Cohort 1 | 0 | 819 |
| Total, other adverse events | Cohort 2 | 0 | 631 |
| Total, serious adverse events | Cohort 1 | 256 | 819 |
| Total, serious adverse events | Cohort 2 | 37 | 631 |
Source ClinicalTrials.gov
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons5
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|---|
| Cohort 1 vs Cohort 2: Number of Participants With Tacrolimus-related Neurotoxicities | Trial comparisons |
| Cohort 1 vs Cohort 2: Number of Participants With Acute Rejection | Trial comparisons |
| Cohort 1 vs Cohort 2: Number of Participants With Tacrolimus-related Nephrotoxicities | Trial comparisons |
| Cohort 1 vs Cohort 2: deaths from any cause | Trial comparisons |
| Cohort 1 vs Cohort 2: serious adverse events | Trial comparisons |
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03083769
GET https://conductscience.org/api/trials/v1/NCT03083769/registered